Sponsored by:

International Management and Coordination by

1st International China Biopharmaceutical Symposium (ICBPS)

•• Vaccines, Antibodies and Gene Therapeutics ••

"development, regulatory approval, production, distribution - China and Worldwide"
7 to 11 December 2006
Beijing, China

           Beijing, China. The Chinese Pharmaceutical Association (CPA) and the China Biochemical Pharmaceutical Industry Association (CBPIA), in association with Battelle Memorial Institute, invite the international community to participate in this first symposium in China in the very exciting area of biopharmaceuticals and the market. With the increasing concern in emerging infectious diseases, bioterrorism events and natural disasters, is there enough access to needed active pharmaceutical ingredients (APIs)?  What can China do to sell its products in all markets and what can other countries do to sell their products in China?  How do Western drug and biotech firms get reliable APIs from China and protect their patents and intellectual property (IP)?  How do Western drug and biotech firms work with Chinese firms to introduce and market their products in China?

            The purpose of this symposium is to introduce the medium and smaller sized Western biotech firms and the regulatory communities, to the Chinese Biopharmaceutical Industries. Learn each others’ capabilities and capacities for product development and manufacturing. Learn the technical, scientific, medical and legal aspects of the processes associated with research and development, drug discovery; and developing and bringing biopharmaceuticals and pharmaceuticals to market in China and in the West.

Latest Abstracts Submitted:

"Choosing Biomarkers for Modeling Medical Treatments"
Barbara B.S. Price, Ph.D.

"General Consideration of Nonclinical Requirement for an IND Prior to Conduct of Clinical Trials"
Maxwell Pan, Ph.D.

Updated by Evan Saunders, 25 April 2006
copyright©2006, ASA Inc. All rights reserved